NCT07247656

The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .

Comparison of Empagliflozin- Linagliptin With Empagliflozin- Metformin Combination Therapy in Reduction of Body Weight in Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Bahria University · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .

Detailed description

The goal of this clinical trial is to evaluate the safety and efficacy of both the drugs combination in evaluating weight loss and glycemic parameters . SPSS version 25 will be used to generate the descriptive statistics. Frequency and percentage figures will be used to represent the qualitative factors. The comparison will be done between male of group A with male of group B and female of group A with female of group B.

Conditions

• Diabete Mellitus

Interventions

Type	Name	Description
DRUG	(Empagliflozin 10 mg+ Tab Linagliptin 5mg)	(Empagliflozin 10 mg+ Tab Linagliptin 5mg)was given once Orally daily
DRUG	Tab Empagliflozin 10 mg + Tab Metformin 500 mg	Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg

Timeline

• Start date: 2022-12-01
• Primary completion: 2023-03-01
• Completion: 2023-05-01
• First posted: 2025-11-25
• Last updated: 2025-11-25

Locations

1 site across 1 country: Pakistan